Abstract
To examine the role of cytochrome P450 2A6 (CYP2A6) in the cellular sensitivity to an anti‐tumor prodrug, tegafur (FT), a CYP2A6 cDNA construct was transfected into cells of a colon cancer cell line, DLD‐1. CYP2A6‐expressing cells (DLD‐1/CYP2A6 cells) more efficiently catalyzed the conversion of FT to 5‐fluorouracil (5‐FU) (2.6‐fold) and the 7‐hydroxylation of coumarin (7.9‐fold) than cells transfected with a null construct (DLD‐1/null cells). These results indicated that the expressed CYP2A6 was functionally active. The extent of growth inhibition of the DLD‐1/CYP2A6 cells by FT was greater than that of DLD‐1/null cells; the difference between the DLD‐1/CYP2A6 and DLD‐1/null cells was statistically significant at the concentrations of 250, 500 and 1000 μM. 5‐FU, an active metabolite of FT, inhibited the growth of both types of cells to the same extent. Thus, intracellular expression of CYP2A6 can sensitize cells to FT.
Keywords: Tegafur, 5, FU, Prodrug, CYP2A6, Tumor cells
Full Text
The Full Text of this article is available as a PDF (128.2 KB).
Reference
- 1.Toide , H. , Akiyoshi , H. , Minato , Y. , Okuda , H. and Fujii , S . Comparative studies on metabolism of 2‐(tetrahydrofuryl)‐5‐fluorouracil and 5‐fluorouracil . Gann , 68 , 553 – 560 ( 1977. ). [PubMed] [Google Scholar]
- 2.Cao , S. , Frank , C. , Shirasaka , T. and Rustum , Y. M . 5‐Flu‐orouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer . Clin. Cancer Res. , 1 , 839 – 843 ( 1995. ). [PubMed] [Google Scholar]
- 3.Hirata , K. , Horikoshi , N. , Aiba , K. , Okazaki , M. , Denno , R. , Sasaki , K. , Nakano , Y. , Ishizuka , H. , Yamada , Y. , Uno , S. , Taguchi , T. and Shirasaka , T . Pharmacokinetic study of S‐l, a novel oral fluorouracil antitumor drug . Clin. Cancer Res. , 5 , 2000 – 2005 ( 1999. ). [PubMed] [Google Scholar]
- 4.Kamataki , T. , Yokoi , T. , Fujita , K.‐I. and Ando , Y . Pre‐clinical approach for identifying drug interactions . Cancer Chemother. Pharmacol. , 42 ( Suppl ), S50 – S53 ( 1998. ). [DOI] [PubMed] [Google Scholar]
- 5.Ikeda , K. , Yoshisue , K. , Matsushima , E. , Nagayama , S. , Kobayashi , K. , Tyson , C. A. , Chiba , K. and Kawaguchi , Y . Bioactivation of tegafur to 5‐fluorouracil is catalyzed by cytochrome P‐450 2A6 in human liver microsomes in vitro . Clin. Cancer Res. , 6 , 4409 – 4415 ( 2000. ). [PubMed] [Google Scholar]
- 6.Komatsu , T. , Yamazaki , H. , Shimada , N. , Nakajima , M. and Yokoi , T . Roles of cytochromes P450 1A2, 2A6 and 2C8 in 5‐fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes . Drug Metab. Dispos. , 28 , 1457 – 1463 ( 2000. ). [PubMed] [Google Scholar]
- 7.Towbin , H. , Staehelin , T. and Gordon , J . Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. . Acad. Sci. USA , 76 , 4350 – 4354 ( 1979. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Pampori , N. A. , Pampori , M. K. and Shapiro , B. H.Dilution of the chemiluminescence reagents reduces the background noise on western blots . Biotechniques , 18 , 588 – 590 ( 1995. ). [PubMed] [Google Scholar]
- 9.El Sayed , Y. M. and Sadee , W . Metabolic activation of R,S‐l‐(tetrahydro‐2‐furanyl)‐5‐fluorouracil (ftorafur) to 5‐fluorouracil by soluble enzymes . Cancer Res. , 43 , 4039 – 4044 ( 1983. ). [PubMed] [Google Scholar]
- 10.Aitio , A . A simple and sensitive assay of 7‐ethoxycou‐marin deethylation . Anal. Biochem. , 85 , 488 – 491 ( 1978. ). [DOI] [PubMed] [Google Scholar]
- 11.Itagaki , H. , Shibata , M. , Tani , N. , Kinoshita , S. , Kakishima , H. , Seyama , Y. , Ohuchi , J. , Kasai , Y. , Okada , J. , Kojima , H. , Okamoto , Y. , Kotani , M. , Ohno , Y. , Miyajima , A. and Takanaka , A . First‐phase inter‐laboratory validation of the in vitro eye irritation tests for cosmetic ingredients. X‐Evaluation of cytotoxicity tests on SIRC cells . AATEX , 3 , 201 – 209 ( 1995. ). [Google Scholar]
- 12.Haraguchi , M. , Furukawa , T. , Sumizawa , T. and Akiyama , S.‐I . Sensitivity of human KB cells expressing plateletderived endothelial cell growth factor to pyrimidine antimetabolites . Cancer Res. , 53 , 5680 – 5682 ( 1993. ). [PubMed] [Google Scholar]
- 13.Koskela , S. , Hakkola , J. , Hukkanen , J. , Pelkonen , O. , Sorri , M. , Saranen , A. , Anttila , S. , Fernandez‐Salguero , P. , Gonzalez , F. and Raunio , H.Expression of CYP2A genes in human liver and extrahepatic tissues . Biochem. Pharmacol. , 57 , 1407 – 1413 ( 1999. ). [DOI] [PubMed] [Google Scholar]
- 14.Meropol , N. J . Oral fluoropyrimidines in the treatment of colorectal cancer . Eur. J. Cancer , 34 , 1509 – 1513 ( 1998. ). [DOI] [PubMed] [Google Scholar]
- 15.Raunio , H. , Juvonen , R. , Pasanen , M. , Pelkonen , O. , Paakko , P. and Soini , Y . Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma . Hepatology , 27 , 427 – 432 ( 1998. ). [DOI] [PubMed] [Google Scholar]
- 16.Nunoya , K.‐L , Yokoi , T. , Kimura , K. , Inoue , K. , Kodama , T. , Funayama , M. , Nagashima , K. , Funae , Y. , Green , C. , Kinoshita , M. and Kamataki , T . A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)‐cis‐3,5‐dimethyl‐2‐(3‐pyridyl)thiazolidin‐4‐one hydrochloride (SM‐12502) . Pharmacogenetics , 8 , 239 – 249 ( 1998. ). [DOI] [PubMed] [Google Scholar]
- 17.Nunoya , K.‐L , Yokoi , T. , Kimura , K. , Kainuma , T. , Satoh , K. , Kinoshita , M. and Kamataki , T . A new CYP2A6 deletion responsible for the in vivo polymorphic metabolism of (+)‐cis‐3,5‐dimethyl‐2‐(3‐pyridyl)thiazolidin‐4‐one hydrochloride in humans . J. Pha.rma.col. Exp. Ther. , 289 , 437 – 442 ( 1999. ). [PubMed] [Google Scholar]
- 18.Nunoya , K. , Yokoi , T. , Takahashi , Y. , Kimura , K. , Kinoshita , M. and Kamataki , T.Homologous unequal cross‐over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype . J. Bio-chem. (Tokyo) , 126 , 402 – 407 ( 1999. ). [DOI] [PubMed] [Google Scholar]